Competing interests
RS, Stock, Cancer
ONCOLOGY, EVENTS, BREAST CANCER, CANCER
SL – Honoraria: Eisai, Prosigna, Roche, Pfizer, Novartis, Sanofi. Advisory: Shionogi, Sanofi, GLG consulting, Rejuversen, Oxford Biodynamics. Research grant funding: CRUK, NIHR, Against Breast Cancer, Pathios Therapeutics. Travel/Accommodation/Expenses: Pfizer, Roche, Synthon, Piqur Therapeutics. Stock holding: Mitox Therapeutics. Previous employment: Pfizer. My institution has received funding for clinical trials for which I am chief investigator or principal investigator from Cancer Research UK, Boehringer Ingelheim, Piqur Therapeutics, AstraZeneca, Carrick Therapeutics, Sanofi, Merck KGaA, Synthon, Roche, Exscientia, BioInvent, RS Oncology. TM – Consulting agreements: AstraZeneca, Ground Truth Laboratories, Perspectum, Teysuno. Employment: National Cancer Research Institute. PS – Honoraria: AZ. Support to attend conferences/educational events: BMS/Takeda. Advisory roles: BMS/Takeda. MAH – Receives funding from University College London Hospitals Biomedical Research Centre. All other authors—no completing interests to declare.